Analyst Consensus ?
ConsensusHold33 ratings
Bullish1648.5%
Neutral1648.5%
Bearish13.0%
Becton, Dickinson and Company · BDX · FY2024 Q3 · Calendar Q3 2024
BD raised FY24 EPS guidance as Alaris and margins strengthened
The quarter supports a constructive view of BD's earnings trajectory: resilient demand in Alaris and connected medication management, alongside operating improvements, drove growth and higher guidance. The thesis is tempered by China, biosciences demand, destocking and acquisition-integration risks.
Reported Before market openNYSEHealthcare
$54.18B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$3.50
Consensus $3.31
EPS surprise
+5.7%
Reported versus consensus
Reported revenue
$4.99B
Consensus $5.08B
Revenue surprise
-1.7%
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
-2.1%
Event window
SPY move
-1.4%
Same window
Abnormal move
-0.7%
Stock minus SPY
Volume
2.6×
Versus trailing sessions
Subsequent drift
+2.1%
Up to 20 sessions
BDXSPY benchmark
Ask FN2 about BDX FY2024 Q3
Transcript, numbers and history already loaded
Why did BDX fall 2.1% after beating EPS estimates in FY2024 Q3?What changed in BDX's guidance and outlook in FY2024 Q3?Give me the bull and bear case for BDX after FY2024 Q3 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Management reported 5.2% organic revenue growth, double-digit margin expansion and 18% adjusted EPS growth. Alaris returned to historic run-rates, the Critical Care acquisition progressed, and FY24 adjusted diluted EPS guidance increased to $13.05-$13.15.
Guidance delta
FY24 adjusted diluted EPS guidance was raised to $13.05-$13.15 from $12.95-$13.15.
Key takeaways
- Organic revenue grew 5.2%, with double-digit margin expansion and 18% adjusted EPS growth.
- Alaris and connected medication management returned to historic run-rates and supported near-term growth.
- The Critical Care acquisition is expected to add AI-enabled monitoring capabilities to BD's connected-care portfolio.
- China market pressure, biosciences research-spending weakness and inventory destocking remain risks.
Management priorities
- Scale Alaris, PureWick and connected medication management
- Advance next-generation Pyxis, RapidRx and smart-factory initiatives
- Integrate Critical Care capabilities and expand AI-enabled monitoring
- Develop GLP-1 delivery and wearable-injector platforms
Follow BDX with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$198.91Current
$159Low
$199.13Average
$235.85High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 24, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| B of A Securities | Neutral | Neutral | Maintain | Aug 31, 2026 |
| RBC Capital | Sector Perform | Sector Perform | Maintain | Aug 13, 2026 |
| Wells Fargo | Equal Weight | Equal Weight | Maintain | Aug 7, 2026 |
| Piper Sandler | Neutral | Neutral | Maintain | Aug 7, 2026 |
| Citigroup | Buy | Buy | Maintain | Aug 7, 2026 |
| TD Cowen | Hold | Hold | Maintain | Aug 5, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Jul 6, 2026 |
| Barclays | Overweight | Overweight | Maintain | May 11, 2026 |
| Argus Research | Buy | Buy | Maintain | Mar 23, 2026 |
| JP Morgan | Neutral | Neutral | Maintain | Feb 10, 2026 |
| Jefferies | Buy | Buy | Maintain | Feb 10, 2026 |
| Stifel | Buy | Buy | Maintain | Jan 7, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Dec 2, 2025 |
| William Blair | Market Perform | Outperform | Downgrade | May 1, 2025 |
| Raymond James | Outperform | Outperform | Maintain | Aug 2, 2024 |
| Keybanc | Overweight | Sector Weight | Upgrade | Apr 12, 2023 |
| Goldman Sachs | Buy | Buy | Maintain | Nov 23, 2022 |
| SVB Leerink | Market Perform | Market Perform | Maintain | Feb 4, 2022 |
| UBS | Neutral | Neutral | Maintain | Aug 10, 2020 |
| CFRA | Hold | Hold | Maintain | May 8, 2020 |
| Cowen & Co. | Market Perform | Outperform | Downgrade | Feb 7, 2020 |
| Stifel Nicolaus | Buy | Buy | Maintain | Dec 16, 2019 |
| BMO Capital | Market Perform | Market Perform | Maintain | May 10, 2019 |
| Deutsche Bank | Buy | Buy | Maintain | Dec 7, 2018 |
| Bank of America | Neutral | Neutral | Maintain | Nov 5, 2014 |
| Canaccord Genuity | Hold | Hold | Maintain | Oct 7, 2014 |
| Argus | Buy | Buy | Maintain | Oct 7, 2014 |
| PiperJaffray | Overweight | Neutral | Upgrade | Sep 18, 2013 |
| ISI Group | Buy | Buy | Maintain | Jun 25, 2013 |
| Macquarie | Outperform | Neutral | Upgrade | May 10, 2013 |
| Mizuho | Neutral | Buy | Downgrade | Jan 22, 2013 |
| Leerink Swann | Market Perform | Outperform | Downgrade | Aug 3, 2012 |
| CLSA | Underperform | Outperform | Downgrade | Aug 3, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $198.91. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Barclays | Christopher Pasquale | $165 | $179.62 | -17.0% | Oct 7, 2026 |
| RBC Capital | Analyst unavailable | $190 | $184.04 | -4.5% | Aug 13, 2026 |
| Stifel Nicolaus | Analyst unavailable | $195 | $176.07 | -2.0% | Aug 7, 2026 |
| RBC Capital | Shagun Singh | $180 | $176.25 | -9.5% | Aug 7, 2026 |
| Jefferies | Analyst unavailable | $210 | $176.91 | +5.6% | Aug 6, 2026 |
| UBS | Analyst unavailable | $190 | $158.92 | -4.5% | Jul 28, 2026 |
| Evercore ISI | Analyst unavailable | $180 | $154.6 | -9.5% | Jul 6, 2026 |
| Barclays | Analyst unavailable | $204 | $149.43 | +2.6% | May 11, 2026 |
| Piper Sandler | Jason Bednar | $159 | $154.82 | -20.1% | Apr 17, 2026 |
| RBC Capital | Analyst unavailable | $175 | $155.43 | -12.0% | Apr 14, 2026 |
| Goldman Sachs | David Roman | $167 | $154.42 | -16.0% | Apr 10, 2026 |
| RBC Capital | Shagun Singh | $172 | $170.14 | -13.5% | Feb 10, 2026 |
| Barclays | Matt Miksic | $202 | $207.39 | +1.6% | Feb 10, 2026 |
| Piper Sandler | Analyst unavailable | $170 | $207.39 | -14.5% | Feb 10, 2026 |
| Piper Sandler | Jason Bednar | $161.16 | $159.91 | -19.0% | Jan 28, 2026 |
| Stifel Nicolaus | Analyst unavailable | $169.03 | $161.45 | -15.0% | Jan 7, 2026 |
| RBC Capital | Analyst unavailable | $165.09 | $154.39 | -17.0% | Dec 17, 2025 |
| Morgan Stanley | Patrick Wood | $165.09 | $150.8 | -17.0% | Dec 2, 2025 |
| Piper Sandler | Jason Bednar | $204.4 | $159.06 | +2.8% | Apr 23, 2025 |
| Evercore ISI | Vijay Kumar | $227.99 | $189.54 | +14.6% | Oct 1, 2024 |
| Citigroup | Joanna Wuensch | $216.19 | $190.2 | +8.7% | Oct 1, 2024 |
| Raymond James | Jayson Bedford | $212.26 | $187.96 | +6.7% | Aug 2, 2024 |
| Wells Fargo | Larry Biegelsen | $220.13 | $185.54 | +10.7% | Aug 2, 2024 |
| Evercore ISI | Becton Dickinson | $224.06 | $180.24 | +12.6% | Jul 2, 2024 |
| Goldman Sachs | David Roman | $215.41 | $176.94 | +8.3% | May 30, 2024 |
| Barclays | Matt Miksic | $245.28 | $184.5 | +23.3% | May 6, 2024 |
| Argus Research | David Toung | $235.85 | $190.83 | +18.6% | Apr 8, 2024 |
| Morgan Stanley | Analyst unavailable | $227.99 | $202.92 | +14.6% | Jan 6, 2023 |
| Citigroup | Analyst unavailable | $196.54 | $194.65 | -1.2% | Dec 12, 2022 |
| Goldman Sachs | Analyst unavailable | $213.84 | $185.9 | +7.5% | Nov 23, 2022 |
| Goldman Sachs | Analyst unavailable | $250.79 | $210.01 | +26.1% | Aug 16, 2022 |
| Stifel Nicolaus | Analyst unavailable | $220.13 | $187.4 | +10.7% | Jul 18, 2022 |
| Morgan Stanley | Analyst unavailable | $213.84 | $187.61 | +7.5% | Jul 15, 2022 |
| Citigroup | Analyst unavailable | $184.75 | $193.13 | -7.1% | Jul 11, 2022 |
| Wells Fargo | Larry Biegelsen | $231.92 | $197.26 | +16.6% | Jun 25, 2022 |
| Morgan Stanley | Analyst unavailable | $221.7 | $197.95 | +11.5% | May 6, 2022 |
| Piper Sandler | Analyst unavailable | $200.47 | $204.12 | +0.8% | May 6, 2022 |
| Bank of America Securities | Travis Steed | $227.99 | $209.27 | +14.6% | Mar 3, 2022 |
| Piper Sandler | Jason Bednar | $208.33 | $206.71 | +4.7% | Feb 3, 2022 |
Track every rating change on BDX the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationOperating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems.…
Historical context
All BDX earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| RDY Dr. Reddy's Laboratories Limited | FY2027 Q2 · Calendar Q4 2026 | +24.0% | -0.2% | Dr. Reddy’s: margins improve as semaglutide rollout advances |
| DGX Quest Diagnostics Incorporated | FY2026 Q3 · Calendar Q4 2026 | +4.5% | +1.8% | Quest Diagnostics: growth broadens, but PAMA remains a headwind |
| ARGX argenx SE | FY2026 Q3 · Calendar Q4 2026 | — | -1.6% | argenx: VYVGART momentum and a broader late-stage pipeline |
| MEDP Medpace Holdings, Inc. | FY2026 Q3 · Calendar Q4 2026 | +9.0% | -1.3% | Medpace: Record awards lift backlog as 2026 outlook improves |
| MOH Molina Healthcare, Inc. | FY2026 Q3 · Calendar Q4 2026 | +12.7% | +0.8% | Molina reaffirms 2026 outlook as Florida contract scales |
Latest beats and misses
Who reports nextBeat on EPS
- FCNCAFY2026 Q3 · October 23, 2026+19.9% EPS+8.2% move
- FCNCNFY2026 Q3 · October 23, 2026+19.9% EPS+0.2% move
- FCNCOFY2026 Q3 · October 23, 2026+19.9% EPS+1.0% move
- FCNCPFY2026 Q3 · October 23, 2026+19.9% EPS+1.0% move
- RDYFY2027 Q2 · October 23, 2026+24.0% EPS-0.2% move
- SLBFY2026 Q3 · October 23, 2026+3.7% EPS+7.1% move
Missed on EPS
- INFYFY2027 Q2 · October 23, 2026-4.8% EPS-6.6% move
- BBDFY2026 Q3 · October 22, 2026-7.7% EPS+3.0% move
- SNAFY2026 Q3 · October 22, 2026-5.9% EPS-3.4% move
- SPOTFY2026 Q3 · October 22, 2026-11.6% EPS+11.1% move
- VRSNFY2026 Q3 · October 22, 2026-2.0% EPS-0.9% move
- HBANMFY2026 Q3 · October 22, 2026-5.3% EPS+0.5% move
Get the BDX recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2024-10-17T05:10:49.140638+00:00
- Polygon adjusted daily market bars · 2026-10-24T22:20:43.761312+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-24T22:20:43.758359+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-24. For educational purposes only; not investment advice.